Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options
Authors
Keywords
-
Journal
Journal of Hepatocellular Carcinoma
Volume Volume 8, Issue -, Pages 387-401
Publisher
Informa UK Limited
Online
2021-05-13
DOI
10.2147/jhc.s300182
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib.
- (2021) Josephine Tsang et al. Expert Review of Gastroenterology & Hepatology
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circular RNA and tumor microenvironment
- (2020) Huixin Song et al. Cancer Cell International
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma
- (2020) Robin Park et al. Vaccines
- Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity
- (2020) Won Suk Lee et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
- (2020) Thomas Yau et al. JAMA Oncology
- Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
- (2020) John D. Gordan et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab and its use in the treatment of hepatocellular carcinoma
- (2019) Fiona Turkes et al. Future Oncology
- Systemic Treatment for Advanced Hepatocellular Carcinoma
- (2019) Mohamed Bouattour et al. Liver Cancer
- Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC).
- (2019) Charalampos S. Floudas et al. JOURNAL OF CLINICAL ONCOLOGY
- Direct Antiviral Agents and the Risk of Recurrence of Hepatocellular Carcinoma: Moving on?
- (2019) Jean-Charles Nault et al. GASTROENTEROLOGY
- Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
- (2019) Thomas Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents
- (2019) Agrin Moeini et al. GASTROENTEROLOGY
- Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma
- (2019) Clifford Akateh et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma
- (2019) Ahmed Omar Kaseb et al. Cancer Immunology Research
- Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?
- (2019) Amit Mahipal et al. Cancers
- Hepatotoxicity of immune check point inhibitors: Approach and management
- (2019) Ana Lleo et al. DIGESTIVE AND LIVER DISEASE
- Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma
- (2019) Ghassan K. Abou-Alfa et al. JAMA Oncology
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- LBA3IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
- (2019) A-L Cheng et al. ANNALS OF ONCOLOGY
- 199TiPPhase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives
- (2019) Grazia Pennisi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Cabozantinib exposure–response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma
- (2019) Linh Nguyen et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
- (2019) David Tai et al. Cancers
- Liver Cancer: Current and Future Trends Using Biomaterials
- (2019) Sue Anne Chew et al. Cancers
- Antiviral Therapy Reduces Hepatocellular Carcinoma Recurrence in Patients With Low HBV-DNA Levels
- (2018) Gang Huang et al. ANNALS OF SURGERY
- Hepatocellular carcinoma in the era of immunotherapy
- (2018) Hao-Wen Sim et al. CURRENT PROBLEMS IN CANCER
- Regorafenib for treatment of hepatocellular carcinoma
- (2018) Morris Sherman HEPATOLOGY
- Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
- (2018) Jorge A. Marrero et al. HEPATOLOGY
- Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide
- (2018) Delphine Maucort-Boulch et al. INTERNATIONAL JOURNAL OF CANCER
- SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
- (2018) Pierce K.H. Chow et al. JOURNAL OF CLINICAL ONCOLOGY
- Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations
- (2018) Jean-Charles Nault et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Hepatocellular carcinoma
- (2018) Alejandro Forner et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
- (2018) Masafumi Ikeda et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.
- (2018) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib as treatment for patients with advanced hepatocellular cancer
- (2017) Kiruthikah Thillai et al. Future Oncology
- Risk for Hepatocellular Carcinoma After Hepatitis C Virus Antiviral Therapy With Direct-Acting Antivirals: Case Closed?
- (2017) Raoel Maan et al. GASTROENTEROLOGY
- Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
- (2017) Daniela Sia et al. GASTROENTEROLOGY
- AASLD guidelines for the treatment of hepatocellular carcinoma
- (2017) Julie K. Heimbach et al. HEPATOLOGY
- Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials
- (2017) Richard Jackson et al. JOURNAL OF CLINICAL ONCOLOGY
- SARAH: a randomised controlled trial comparing efficacy and safety of selective internal radiation therapy (with yttrium-90 microspheres) and sorafenib in patients with locally advanced hepatocellular carcinoma
- (2017) V. Vilgrain et al. JOURNAL OF HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Human primary liver cancer–derived organoid cultures for disease modeling and drug screening
- (2017) Laura Broutier et al. NATURE MEDICINE
- The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level
- (2017) et al. JAMA Oncology
- Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma
- (2016) Joseph Ralph Kallini et al. ADVANCES IN THERAPY
- Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer
- (2016) A. Blythe Ryerson et al. CANCER
- Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated With Nonalcoholic Fatty Liver Disease
- (2016) Sahil Mittal et al. Clinical Gastroenterology and Hepatology
- Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
- (2016) Kenji Ikeda et al. JOURNAL OF GASTROENTEROLOGY
- Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival
- (2016) Omar Abdel-Rahman et al. Expert Review of Gastroenterology & Hepatology
- Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and management
- (2015) B. McLellan et al. ANNALS OF ONCOLOGY
- A Comparison of the Surgical Outcomes Among Patients With HBV-positive, HCV-positive, and Non-B Non-C Hepatocellular Carcinoma
- (2015) Tohru Utsunomiya et al. ANNALS OF SURGERY
- SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
- (2015) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Radioembolisation and portal vein embolization before resection of large hepatocellular carcinoma
- (2015) Fikri Bouazza WORLD JOURNAL OF GASTROENTEROLOGY
- Capturing hepatocellular carcinoma cells using lactobionic acid-functionalized electrospun polyvinyl alcohol/polyethyleneimine nanofibers
- (2015) Yili Zhao et al. RSC Advances
- Adjuvant Iodine131Lipiodol after Resection of Hepatocellular Carcinoma
- (2015) Ruelan V. Furtado et al. Journal of Oncology
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Radiofrequency Ablation With or Without Transcatheter Arterial Chemoembolization
- (2013) Daniel H. Palmer JOURNAL OF CLINICAL ONCOLOGY
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia
- (2013) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation
- (2013) Maurizio Pompili WORLD JOURNAL OF GASTROENTEROLOGY
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
- (2012) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Sequential Transcatheter Arterial Chemoembolization and Portal Vein Embolization versus Portal Vein Embolization Only before Major Hepatectomy for Patients with Hepatocellular Carcinoma
- (2010) Hyunkyung Yoo et al. ANNALS OF SURGICAL ONCOLOGY
- The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis
- (2010) Mustafa S. Ascha et al. HEPATOLOGY
- Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib
- (2010) B. Vincenzi et al. ONCOLOGIST
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation